Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lauren Eisenberg

Urology El Paso, TX Doctor of Osteopathy

NPI 1053511279 CMS profile 319944

7420 Remcon Circle, Bldg. A, El Paso, TX 79912

Open in the dashboard

General payments

$4,877

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Eisenberg of El Paso, TX is reported in the CMS Open Payments database as having received $4,877 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $659 33
2024 General $845 28
2023 General $952 24
2022 General $558 23
2021 General $602 24
2020 General $281 9
2019 General $981 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Eisenberg
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Lauren Eisenberg were reported at $659. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Lauren Eisenberg Urology median Middle half National median
2019 $981 $480 $147–$1,201 $163
2020 $281 $246 $87–$645 $114
2021 $602 $358 $111–$1,000 $132
2022 $558 $476 $143–$1,263 $149
2023 $952 $560 $168–$1,461 $160
2024 $845 $563 $170–$1,464 $164
2025 $659 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $594 28 payments
  2. Axonics Modulation Technologies, Inc. $467 21 payments
  3. Boston Scientific Corporation $362 10 payments
  4. AbbVie, Inc. $353 18 payments
  5. Ge Healthcare $327 3 payments
  6. Sumitomo Pharma America, Inc. $327 20 payments
  7. Janssen Biotech, Inc. $322 29 payments
  8. Urogen Pharma, Inc. $252 4 payments
  9. Calyxo, Inc. $231 6 payments
  10. Medtronic, Inc. $205 8 payments
  11. Other $1,437 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,777 192 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $415 23 payments
  2. Axonics $386 16 payments
  3. GEMTESA $353 22 payments
  4. ERLEADA $322 29 payments
  5. JELMYTO $225 3 payments
  6. INTERSTIM $205 8 payments
  7. XTANDI $185 10 payments
  8. LUPRON DEPOT $182 10 payments
  9. PROVENGE $181 1 payment
  10. CVAC ASPIRATION SYSTEM $177 5 payments
  11. Other $2,006 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,148

Median for Urology: 1,053

Drug cost

$331,089

Median for Urology: $101,464

Branded share of claims

50.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 261 $158,746
Myrbetriq Mirabegron Brand 198 $145,602
Silodosin Generic 76 $4,285
Estradiol Generic 60 $3,855
Tamsulosin Hcl Generic 260 $2,713
Cefuroxime Cefuroxime Axetil Brand 242 $2,310
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 113 $2,297
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 89 $2,121
Cephalexin Generic 245 $1,917
Methenamine Hippurate Generic 32 $1,470

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$170,279

Of which drugs: $12,670

Medicare patients

556

Average age 75

Services billed

4,594

318 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 37%
Chronic kidney disease 36%
Ischemic heart disease 24%
Cancer 22%
Depression 22%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $113
$113 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $92
$92 261 —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $45
$45 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $17
$17 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record